Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Edward B. Garon, MD

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

While it is understood that these agents may work in the second-line setting for some patients, to date, researchers and clinicians are still unsure whether some patients would have more of a benefit holding a select treatment off until a later setting.

However, Garon mentioned that by examining data from recent clinical trials, researchers might be able to determine appropriate patients to receive PD-1/PD-L1 inhibitors as salvage therapy.

<<< View more from the 2017 Chemotherapy Foundation Symposium
Printer Printing...